Serious adverse events attributable to the drug · people with confirmed COVID‐19
Favipiravir showed no clear difference in serious adverse events attributable to the drug compared with no treatment, supportive treatment, or other antiviral treatment (low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (the number of acute URTIs over a period of time) · children up to the age of 7 at risk of upper respiratory tract infection
Summary of findings table ‐ Vitamin A supplements showed no clear difference in incidence of acute URTIs during the study period (the number of… compared with placebo (low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (proportion of participants with an acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Adverse events · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Severity of subjective symptoms (mean duration of acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Time to occurrence of acute URTI ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of cases with complications ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of hospitalisation ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BMI short‐term (12 weeks from baseline to < 9 months) · children aged 5 to 11 years
1 finding from 1 review
Body‐mass index (BMI) · children aged 5 to 11 years
2 findings from 1 review
zBMI short term (12 weeks from baseline to < 9 months) · children aged 5 to 11 years
1 finding from 1 review
zBMI medium term (9 months to < 15 months) · children aged 5 to 11 years
1 finding from 1 review
zBMI long term (> 15 months) · children aged 5 to 11 years
1 finding from 1 review
Serious adverse events · children aged 5 to 11 years
1 finding from 1 review
BMI short‐term (12 weeks from baseline to < 9 months) · children aged 5 to 11 years
1 finding from 1 review
Body‐mass index (BMI) · children aged 5 to 11 years
2 findings from 1 review
zBMI short term (12 weeks from baseline to < 9 months) · children aged 5 to 11 years
1 finding from 1 review
zBMI medium term (9 months to < 15 months) · children aged 5 to 11 years
1 finding from 1 review
Body‐mass index (BMI) · children aged 5 to 11 years
2 findings from 1 review
zBMI long term (> 15 months) · children aged 5 to 11 years
1 finding from 1 review